Tetraphase Pharmaceuticals’ (TTPH) “Hold” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their hold rating on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a research report sent to investors on Wednesday morning, AnalystRatings.com reports.

Other analysts also recently issued reports about the company. Needham & Company LLC reiterated a hold rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, August 11th. ValuEngine upgraded Tetraphase Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, November 1st. Gabelli upgraded Tetraphase Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, October 31st. Finally, G.Research upgraded Tetraphase Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, October 31st. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Tetraphase Pharmaceuticals currently has an average rating of Buy and a consensus price target of $58.00.

Shares of NASDAQ TTPH traded up $0.01 during midday trading on Wednesday, hitting $2.47. 80,900 shares of the company’s stock were exchanged, compared to its average volume of 117,982. The firm’s fifty day simple moving average is $4.02 and its 200-day simple moving average is $1.41. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.70 and a quick ratio of 3.95. The company has a market cap of $7.42 million, a PE ratio of -0.09 and a beta of 2.36. Tetraphase Pharmaceuticals has a twelve month low of $2.26 and a twelve month high of $39.40.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($6.00) EPS for the quarter, topping the Zacks’ consensus estimate of ($6.27) by $0.27. The company had revenue of $3.34 million for the quarter, compared to the consensus estimate of $1.55 million. Tetraphase Pharmaceuticals had a negative return on equity of 152.06% and a negative net margin of 804.43%. Equities analysts anticipate that Tetraphase Pharmaceuticals will post -26.51 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TTPH. JPMorgan Chase & Co. raised its holdings in shares of Tetraphase Pharmaceuticals by 803.7% in the second quarter. JPMorgan Chase & Co. now owns 116,428 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 103,544 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Tetraphase Pharmaceuticals by 17.3% in the second quarter. Renaissance Technologies LLC now owns 2,613,230 shares of the biopharmaceutical company’s stock worth $1,255,000 after acquiring an additional 386,045 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Tetraphase Pharmaceuticals by 7.4% in the second quarter. Vanguard Group Inc. now owns 2,514,773 shares of the biopharmaceutical company’s stock worth $1,208,000 after acquiring an additional 173,053 shares during the last quarter. Paloma Partners Management Co acquired a new position in shares of Tetraphase Pharmaceuticals in the second quarter worth $115,000. Finally, Jane Street Group LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the second quarter worth $122,000.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Story: Why is the LIBOR significant?

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.